Posted by Michael Wonder on 26 Apr 2022
Amarin partner HLS Therapeutics completes reimbursement negotiations with Pan-Canadian Pharmaceutical Alliance for Vascepa (icosapent ethyl)
26 April 2022 - Amarin Corporation announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance for the terms and conditions under which Vascepa (icosapent ethyl) would qualify for public market reimbursement in Canada.
Following these negotiations, HLS has signed a Letter of Intent which allows HLS to work with all participating provincial jurisdictions to secure coverage from publicly funded drug plans across Canada, and for Vascepa to potentially be added to their respective plans.
